Bill Newell's guest appearances

Bill Newell

HUMAN PROOF OF CONCEPT

ForbesBooks Radio

Biotech 2050 Podcast

Ron Cohen

Robert Gould

Jim Burns

David Berry

David Bates

Jim Sullivan

Tim Sweeney

Tim Miller

Andrew Miller

Chris Wright

Joe Allen

James Mackay

Atopic Dermatitis

Thomas Barnes

Marty Moore

OwlTail

Sutro Biopharma

William J. Newell has served as our Chief Executive Officer and a member of our Board of Directors since January 2009. Previously, he served as the President of Aerovance, Inc., a biotechnology company focused on respiratory diseases, from 2006 to 2007. Mr. Newell has also served as the Chief Business Officer and Senior Vice President at QLT Inc., in several senior management positions at Axys Pharmaceuticals, Inc., and has experience as a corporate lawyer. He currently serves on the boards of directors of a private biotechnology company, the Biotechnology Innovation Organization’s Health Section and Emerging Company Section and the California Life Sciences Association, where he also serves as a member of the executive committee. Mr. Newell received an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan Law School. We believe that Mr. Newell is qualified to serve on our Board of Directors because of his experience with various biotechnology companies, including working with and serving in various executive positions in life sciences companies.

47. Next generation cell-free cancer and autoimmune therapeutics, Bill Newell, CEO, Sutro Biopharma

Bill Newell is a lawyer turned large molecule wrangler. He’s CEO of Sutro Biopharma, and their special sauce - literally - lets them manipulate and manufacture antibodies with the kind of control scientists have had over small molecules for decades.Where other biotechs find scientific challenges can threaten their survival, with Sutro it comes down to strategic challenges. And Bill has led them to enviable partnerships, capital, and optionality.Sutro has an unfair advantage: Bill Newell.

Bill Newell is a lawyer turned large molecule wrangler. He’s CEO of Sutro Biopharma, and their special sauce - literally - lets them manipulate and manufacture antibodies with the kind of control scientists have had over small molecules for decades.<br><br>Where other biotechs find scientific challenges can threaten their survival, with Sutro it comes down to strategic challenges. And Bill has led them to enviable partnerships, capital, and optionality.<br><br>Sutro has an unfair advantage: Bill Newell.

Bill Newell: Sutro has an Unfair Advantage